|
Manufacturing review of the cangaroo envelope device history record for the reported lot shows that all packaged and labeled units were quality released to distribution on 07/23/2020 having met all internal qc acceptance requirements.All sterilization processing records and bioburden testing indicate a successful sterilization cycle and passing results of product lal and sterility samples allowing the subassembly lot to be released for further packaging and labeling having met all criteria for release.Any non-conformances during manufacturing or sterilization potentially impacting the final acceptance of this manufacturing lot were successfully resolved prior to lot release and not associated with the reported event.In lieu of a request for the oem supplier dhr review, it is noted that aziyo processes the non-sterile envelope materials including cutting, suturing, packaging and sterilizing the product.It is also noted that per the instructions for use (ifu - art-20662) provided with the finished cangaroo envelope device, hematoma is listed as a potential complication associated with the procedure and device.Although the exact cause of the reported hematoma cannot be conclusively determined, hematomas are a known complication associated with the use of a cangaroo envelope and a surgical implant procedure.Should aziyo receive any additional details related to this event, a supplemental report will be filed.
|
|
It was reported by aziyo biologics' business partner boston scientific, that a cangaroo envelope (model # cmcv-009-xlg, lot# m20g1218) was implanted (date unknown) with a boston scientific crt-d (model# / serial # - unknown).The patient underwent a hematoma evacuation procedure on (b)(6) 2020 and ultimately a device extraction on (b)(6) 2020.No further information is available at the time of this filing.Should any additional details be received by aziyo, a supplemental report will be filed.
|